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Gastroesophageal reflux disease (GERD) usually requires
long-term therapy. Treatment strategies include proton
pump inhibitor (PPI) or H2receptor-antagonists (H2RA),
or prokinetic agents.
OBJECTIVE: A decision tree analytic model for compar-
ing economic and clinical outcomes of GERD treatment
strategies using continuous or intermittent therapy with
PPI, H2RA, or prokinetic agents was developed.
METHODS: Two decision tree models were constructed.
One compared four continuous drug therapies; the other
compared four intermittent drug treatments. Base values
for heal rates and relapse frequencies were determined by
analysis of published clinical data. Costs were drug, phy-
sician visit, endoscopy, and surgery costs. Clinical out-
comes (percent of patients asymptomatic) and economic
outcomes (direct costs) were determined at 12 months.
RESULTS: The four continuous treatment strategies re-
sulted in 99-100% asymptomatic patients at 1 year
whereas the four intermittent strategies resulted in 76-
80% asymptomatic patients at 1 year. At 1 year, the costs
per asymptomatic patient, for continuous treatment strat-
egies, were $1069, $1083, $1164, and $1193 for ome-
prazole 20 mg daily initially followed by omeprazole 10
mg, omeprazole 20 mg, or ranitidine 300 mg daily, or
ranitidine 300 mg daily continuously, respectively, and,
for intermittent strategy, were $1299, $1304, $1353, and
$1455 for omeprazole 20 mg, cisapride 40 mg daily fol-
lowed by omeprazole for failures, ranitidine 300 mg daily
followed by omeprazole for failures, and ranitidine 300
mg daily followed by ranitidine 600 mg daily. Sensitivity
analyses showed omeprazole cost and healing rate to
have the greatest impact on the cost of treatment.
CONCLUSIONS: These GERD decision tree analytic
models are useful tools for comparing economic and clin-
ical outcomes of drug treatment strategies over a wide
range of costs and clinical efficacies.
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OBJECTIVE: To determine (1) whether women taking
alendronate for osteoporosis comply with instructions for
use, (2) the prevalence of gastrointestinal (GI) symptoms,
(3) continuance with treatment, and (4) frequency with
which women taking alendronate require medical care
for acid-related GI disorders (ARDs).
METHODS: Retrospective database analysis and tele-
phone interview survey of 812 women, mean age 68.7 ::':::
11.7 years, in the Kaiser Permanente Medical Care Pro-
gram.
RESULTS: During therapy, 55.8% did not comply with
?:1 instructions: 13.5% did not comply with ?:1 safety
rules and 51.7% with ?:1 absorption guidelines. Nearly a
third of the women reported new ARDs associated with
alendronate. Database analysis of alendronate users re-
vealed that the risk of an ARD was greater among
women with a previous ARD (RR = 3.0; CI = 1.9, 4.9)
and those who used nonsteroidal anti-inflammatory drug
(RR = 1.7; CI = 1.1, 2.6) or H2 blockers or proton
pump inhibitors (RR = 3.8; CI = 2.3, 6.0 [adjusted for
prior ARD]). Compared with a reference group of non-
users, alendronate users had a 1.6-fold higher rate of new
ARDs (95% CI = 1.0, 2.5). A significant (p < 0.05) dif-
ference in the rate of new ARD encounters was observed
for women ?:75 years, in whom a 2.1-fold higher ARD
rate was observed compared with nonusers. During alen-
dronate therapy, 12.3% of the women received care for
an ARD. By the end of a 10-month follow-up, 46.1 % of
the women had discontinued therapy, usually because of
GI problems.
CONCLUSIONS: Lack of compliance is common among
women taking alendronate. About 1 in 3 women have
ARDs during alendronate therapy and 1 in 8 require
medical care for them. The added costs of medical care
should be factored into the cost/benefit analysis of alen-
dronate treatment for osteoporosis.
